LakeShore Financial Statements From 2010 to 2026

LSBCF Stock   0.06  0.02  19.50%   
LakeShore Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LakeShore Biopharma's valuation are provided below:
Enterprise Value Revenue
0.6578
There are over one hundred nineteen available fundamental ratios for LakeShore Biopharma, which can be analyzed over time and compared to other ratios. Active traders should verify all of LakeShore Biopharma last-minute fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The current Market Cap is estimated to decrease to about 2.1 B. Enterprise Value is estimated to decrease to about 2.5 B

LakeShore Biopharma Total Revenue

579.82 Million

Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.4 M, Interest Expense of 27.1 M or Selling General Administrative of 134.5 M, as well as many indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0 or PTB Ratio of 4.16. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Build AI portfolio with LakeShore Stock
Check out the analysis of LakeShore Biopharma Correlation against competitors.

LakeShore Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.6 B437.2 M
Slightly volatile
Short and Long Term Debt Total382.1 M476.6 M163.7 M
Slightly volatile
Total Current Liabilities578.8 M948.5 M447.6 M
Slightly volatile
Total Stockholder Equity521.8 M449.8 M705.8 M
Slightly volatile
Property Plant And Equipment Net505.2 M476.5 M341.9 M
Slightly volatile
Current Deferred Revenue1.6 M1.3 MM
Slightly volatile
Accounts Payable53.9 M57 M30.6 M
Slightly volatile
Cash24 M25.3 M309.4 M
Slightly volatile
Non Current Assets Total444.2 M604.3 M180.5 M
Slightly volatile
Cash And Short Term Investments24 M25.3 M309.4 M
Slightly volatile
Net Receivables426.2 M577.1 M299.1 M
Slightly volatile
Common Stock Shares Outstanding76.9 M123 M49.2 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.6 B437.2 M
Slightly volatile
Non Current Liabilities Total36.9 M38.8 M912.5 M
Slightly volatile
Inventory190.2 M261.7 M125.3 M
Slightly volatile
Other Current Assets102.3 M97.5 M49.4 M
Slightly volatile
Other Stockholder Equity2.2 B3.4 B1.4 B
Slightly volatile
Total Liabilities617.6 M998.1 M260.2 M
Slightly volatile
Total Current Assets941.5 M968.6 M795.4 M
Slightly volatile
Short Term Debt227.3 M449.5 M103 M
Slightly volatile
Intangible Assets61.9 M65.6 M79.5 M
Slightly volatile
Common Stock18.3 K32.9 K12.6 K
Slightly volatile
Long Term Debt20.1 M21.2 M206.2 M
Slightly volatile
Capital Lease Obligations390.7 K411.3 K11.7 M
Slightly volatile
Property Plant And Equipment Gross613.4 M660.6 M737.6 M
Slightly volatile
Short and Long Term Debt279 M449 M174.8 M
Slightly volatile
Capital Stock20.6 K32.9 K12.7 K
Slightly volatile
Net Working Capital14.9 M15.7 M234.9 M
Slightly volatile

LakeShore Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization38.4 M42.1 M31.4 M
Slightly volatile
Interest Expense27.1 M18.1 M27.4 M
Slightly volatile
Selling General Administrative134.5 M156.4 M134.8 M
Pretty Stable
Selling And Marketing Expenses224.8 M293 M131.4 M
Slightly volatile
Total Revenue579.8 M707.2 M381.9 M
Slightly volatile
Gross Profit456.6 M583.3 M299.4 M
Slightly volatile
Other Operating Expenses781.4 M806.4 M527.5 M
Slightly volatile
Research Development236.2 M168.3 M142.5 M
Slightly volatile
Cost Of Revenue123.2 M123.9 M82.6 M
Slightly volatile
Total Operating Expenses658.2 M682.5 M445 M
Slightly volatile
Reconciled Depreciation40.3 M42.1 M33.6 M
Slightly volatile

LakeShore Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.8 M12.2 M53.5 M
Slightly volatile
Begin Period Cash Flow281.7 M283.5 M109.8 M
Slightly volatile
Other Cashflows From Financing Activities378.4 M194.9 M556.7 M
Slightly volatile
Depreciation38.4 M42.1 M31.4 M
Slightly volatile
Other Non Cash Items54.8 M55.8 M24.3 M
Slightly volatile
Capital Expenditures15.3 M16.1 M94.3 M
Slightly volatile
End Period Cash Flow178.5 M96.7 M311.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.383.5548.979
Slightly volatile
PTB Ratio4.164.3718.4479
Slightly volatile
Days Sales Outstanding217268288
Slightly volatile
Book Value Per Share4.114.212.0005
Slightly volatile
Average Payables50.2 M52.8 M56.4 M
Pretty Stable
Stock Based Compensation To Revenue0.02410.02540.1997
Slightly volatile
Capex To Depreciation0.530.563.2424
Slightly volatile
PB Ratio4.164.3718.4479
Slightly volatile
EV To Sales4.064.2848.2051
Slightly volatile
Inventory Turnover0.740.540.7027
Slightly volatile
Days Of Inventory On Hand455694528
Slightly volatile
Payables Turnover2.952.53.2509
Slightly volatile
Sales General And Administrative To Revenue0.30.250.4297
Slightly volatile
Average Inventory140.8 M158.3 M172.8 M
Slightly volatile
Research And Ddevelopement To Revenue0.440.270.3764
Very volatile
Capex To Revenue0.03170.03340.314
Slightly volatile
Cash Per Share0.290.39.7952
Slightly volatile
Days Payables Outstanding122151120
Slightly volatile
Income Quality0.71.091.0562
Slightly volatile
Intangibles To Total Assets0.05820.0613593
Slightly volatile
Current Ratio1.121.17317
Pretty Stable
Receivables Turnover1.51.411.2767
Slightly volatile
Shareholders Equity Per Share5.115.3820.5843
Slightly volatile
Debt To Equity0.460.750.2518
Slightly volatile
Capex Per Share0.180.193.0559
Slightly volatile
Average Receivables378.4 M425.7 M464.6 M
Slightly volatile
Revenue Per Share10.126.618.9474
Very volatile
Interest Debt Per Share6.584.633.4097
Slightly volatile
Debt To Assets0.330.35133
Slightly volatile
Operating Cycle672962815
Pretty Stable
Price Book Value Ratio4.164.3718.4479
Slightly volatile
Days Of Payables Outstanding122151120
Slightly volatile
Ebt Per Ebit1.691.351.5234
Very volatile
Company Equity Multiplier1.282.460.6896
Slightly volatile
Long Term Debt To Capitalization0.04910.05170.0511
Slightly volatile
Total Debt To Capitalization0.260.410.1512
Slightly volatile
Debt Equity Ratio0.460.750.2518
Slightly volatile
Quick Ratio0.810.86248
Pretty Stable
Net Income Per E B T0.991.140.9799
Pretty Stable
Cash Ratio0.03720.0392113
Pretty Stable
Cash Conversion Cycle550811696
Very volatile
Days Of Inventory Outstanding455694528
Slightly volatile
Days Of Sales Outstanding217268288
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.3230.0196
Pretty Stable
Price To Book Ratio4.164.3718.4479
Slightly volatile
Fixed Asset Turnover0.921.341.0683
Slightly volatile
Debt Ratio0.330.35133
Slightly volatile
Price Sales Ratio3.383.5548.979
Slightly volatile
Asset Turnover0.490.521.8 K
Slightly volatile
Gross Profit Margin0.620.740.7624
Slightly volatile
Price Fair Value4.164.3718.4479
Slightly volatile

LakeShore Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 B2.2 B7.2 B
Slightly volatile
Enterprise Value2.5 B2.6 B7.4 B
Slightly volatile

LakeShore Fundamental Market Drivers

About LakeShore Biopharma Financial Statements

LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.6 M
Total Revenue707.2 M579.8 M
Cost Of Revenue123.9 M123.2 M
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.25  0.30 
Research And Ddevelopement To Revenue 0.27  0.44 
Capex To Revenue 0.03  0.03 
Revenue Per Share 6.61  10.12 
Ebit Per Revenue(0.14)(0.13)

Currently Active Assets on Macroaxis

When determining whether LakeShore Biopharma is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:
Check out the analysis of LakeShore Biopharma Correlation against competitors.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.